Whitehawk Therapeutics, Inc. (WHWK) intrinsic value & 10-year financials
Whitehawk Therapeutics, Inc. (WHWK) has a Graham intrinsic value of $5.42 per share. At $2.89 on Oct 17, 2026, the stock trades 47% below that value. Over the last 10 fiscal years revenue shrank 13.8% a year to $7.1M, with an average return on invested capital of 256.7%.
- Graham intrinsic value
- $5.42
- Share price (Oct 17, 2026)
- $2.89
- Price vs Graham value
- 47% below
- Market cap
- $178.9M
- Revenue (FY2025)
- $7.1M
- Revenue growth (10-yr CAGR)
- -13.8%
- ROIC (10-yr avg)
- 256.7%
- Free cash flow (FY2025)
- -$98.0M
WHWK 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.1M | -$20.6M | -$0.33 | -$98.0M | -1601.1% | -185.8% |
| FY2024 | $26.0M | -$63.7M | -$2.36 | -$61.2M | -259.6% | -199.8% |
| FY2023 | $24.4M | -$65.8M | -$2.44 | -$63.6M | -295.4% | -87.8% |
| FY2022 | $15.2M | -$60.5M | -$2.69 | -$50.1M | -411.9% | -115.5% |
| FY2021 | $1.1M | -$110.1M | -$12.41 | -$22.5M | -9930.1% | 918.5% |
| FY2020 | $15.0M | -$4.3M | — | -$5.4M | -42.4% | — |
| FY2019 | $0 | -$23.3M | — | -$24.1M | — | 1210.9% |
| FY2018 | $20.2M | -$10.4M | — | -$5.8M | -55.5% | — |
| FY2017 | — | -$21.4M | — | -$18.9M | — | — |
| FY2016 | — | -$39.4K | — | -$137.8K | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Whitehawk Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Whitehawk Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -31.0% ROIC.
Whitehawk Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Whitehawk Therapeutics, Inc. is modeled at -13.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $5.42 per share.